CA
ATHE

Claro Advisors’s Alterity Therapeutics ATHE Stock Holding History

Claro Advisors’s Portfolio ATHE Stock Details ATHE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-224
Closed -$5K – 202
2018
Q4 		$5K Buy
+224
New +$3.89K ﹤0.01% 774

Other funds holding ATHE

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
AG
Advisor Group Phoenix, Arizona $14.5B AUM 24.86% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
AIM
Advantage Investment Management Cedar Rapids, Iowa $128M AUM 0.94% 1-Year Est. Return
NFG
Next Financial Group Houston, Texas $1.52B AUM 20.14% 1-Year Est. Return
NFH
NEXT Financial Holdings Houston, Texas $395M AUM
APA
American Portfolios Advisors Holbrook, New York $2.36B AUM 14.59% 1-Year Est. Return

Claro Advisors's ATHE Position: Q1 2019 in Review

Claro Advisors sold out of Alterity Therapeutics (ATHE) in Q1 2019, closing a stake of 224 shares — an estimated $5K sold.

Claro Advisors first reported a position in ATHE in Q4 2018 and held it in 1 quarter. The position peaked at $5K in Q4 2018. 8 funds tracked by Wall St. Rank hold ATHE as of Q1 2019.

  • Claro Advisors reported no remaining Alterity Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Claro Advisors sold 224 Alterity Therapeutics shares in Q1 2019, an estimated $5K.
  • Claro Advisors first reported a position in Alterity Therapeutics in Q4 2018 and held it in 1 quarter.
  • Claro Advisors's Alterity Therapeutics position peaked at $5K in Q4 2018.
  • 8 funds tracked by Wall St. Rank held Alterity Therapeutics as of Q1 2019.

Based on Claro Advisors's 13F filing for Q1 2019, filed 10 May 2019.